Company Analysis

Aytu BioPharma, Inc. (AYTU)

Nasdaq: AYTU · Pharmaceutical Preparations · Denver, CO · filing with the SEC since 2007
Grade4.2
◀ Past 3.5● Present 5.3▶ Future 3.5
1 est.

Filings

533 filings since 2017 beside 145 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company
10-Q Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by Nov 14, 2026
10-K Annual report for the fiscal year ending Jun 30, 2027Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Sep 28, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 84 days after the quarter ended. The proxy statement was last filed Oct 22, 2026.

Filings a yearinsider forms included
76120598062395822
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 2 times in the last 36 months, the newest May 21, 2025.SEC letters: 5 in the last 36 months, the newest Jun 2, 2025.
Insider forms 145

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Oct 27, 2026 DEFA14A Extra proxy material
Oct 22, 2026 DEF 14A Proxy statement Dec 10, 2026
Sep 22, 2026 10-K Annual report Jun 30, 2026
Sep 22, 2026 8-K items 2.02, 9.01 Results released · Current report
Aug 14, 2026 SCHEDULE 13G/A Large holder update, amended
Jun 25, 2026 8-K item 1.02 Major agreement ended · Current report Jun 23, 2026
May 13, 2026 10-Q Quarterly report Mar 31, 2026
May 13, 2026 8-K items 2.02, 9.01 Results released · Current report
Apr 2, 2026 8-K items 1.01, 2.02, 3.02, 3.03, 9.01 Major agreement signed; Results released; Shares sold without registration; Change to shareholders' rights · Current report Mar 31, 2026
Feb 17, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 13, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 3, 2026 10-Q Quarterly report Dec 31, 2025
Feb 3, 2026 8-K items 2.02, 9.01 Results released · Current report
Jan 20, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Dec 10, 2025 8-K item 5.07 Shareholder vote · Current report
Nov 14, 2025 SCHEDULE 13G/A Large holder update, amended
Nov 13, 2025 10-Q Quarterly report Sep 30, 2025
Nov 13, 2025 8-K items 2.02, 9.01 Results released · Current report
Nov 12, 2025 SCHEDULE 13G/A Large holder update, amended
Oct 24, 2025 ARS Annual report to shareholders Jun 30, 2025
Oct 24, 2025 DEFA14A Extra proxy material
Oct 24, 2025 DEF 14A Proxy statement Dec 10, 2025
Sep 23, 2025 S-8 Employee stock plan registration
Sep 23, 2025 10-K Annual report Jun 30, 2025
Sep 23, 2025 8-K items 2.02, 9.01 Results released · Current report
Aug 14, 2025 SCHEDULE 13G Large holder notice
Aug 13, 2025 SCHEDULE 13G/A Large holder update, amended
Aug 7, 2025 8-K item 1.02 Major agreement ended · Current report Aug 5, 2025
Jun 26, 2025 SCHEDULE 13G Large holder notice
Jun 26, 2025 SCHEDULE 13G/A Large holder update, amended
Jun 26, 2025 SCHEDULE 13G/A Large holder update, amended
Jun 26, 2025 SCHEDULE 13G Large holder notice
Jun 23, 2025 8-K items 1.01, 2.03, 7.01, 9.01 Major agreement signed; New debt or obligation taken on; Investor disclosure (Regulation FD) · Current report Jun 20, 2025
Jun 17, 2025 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Jun 13, 2025 SCHEDULE 13G Large holder notice
Jun 9, 2025 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Jun 9, 2025 424B4 Offering prospectus
Jun 9, 2025 SCHEDULE 13D/A Activist holder update, amended
Jun 6, 2025 8-K items 1.01, 7.01, 9.01 Major agreement signed; Investor disclosure (Regulation FD) · Current report Jun 5, 2025
Jun 6, 2025 8-K items 1.01, 2.01, 7.01, 9.01 Major agreement signed; Purchase or sale of a business completed; Investor disclosure (Regulation FD) · Current report Jun 5, 2025
40 of 533 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton AYTU · research, not advice